25 January 2026 : Clinical Research
Comparison of Ciprofol-Nalbuphine and Propofol-Nalbuphine Sedation During Painless Gastrointestinal Endoscopy: A Randomized Controlled Trial
Zhong Zhang BCE 1, Wei Jiang ABF 1, Longjiao Zheng BCF 1, Zhiyang Yu ACDE 1*DOI: 10.12659/MSM.951195
Med Sci Monit 2026; 32:e951195
Table 3 Adverse events.
| Outcomes | Propofol (n=64) | Ciprofol (n=64) | χ2 | P |
|---|---|---|---|---|
| Hypotension | 5 (7.8%) | 1 (1.6%) | ||
| Bradycardia | 2 (3.1%) | 1 (1.6%) | ||
| Hypoxemia | 5 (7.8%) | 1 (1.6%) | ||
| Total incidence rate | 10 (18.7%) | 3 (4.8%) | 4.833 | 0.028 |
| Injection pain | 9 (14.1%) | 0 (0%) | ||
| Cough | 7 (10.9%) | 5 (7.8%) | ||
| Body movement | 1 (1.6%) | 1 (1.6%) | ||
| Total incidence rate | 17 (26.6%) | 6 (9.4%) | 6.413 | 0.011 |
| Tachycardia | 2 (3.1%) | 1 (1.6%) | ||
| Upper respiratory obstruction | 5 (7.8%) | 1 (1.6%) | ||
| Apnea | 2 (3.1%) | 1 (1.6%) | ||
| Vasoactive drugs | 5 (7.8%) | 1 (1.6%) | ||
| Total incidence rate | 14 (21.9%) | 4 (6.4%) | 5.236 | 0.022 |